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Abstract
Fetal hypoxia is a common complication of pregnancy. It has been shown to programme cardiac and endothelial
dysfunction in the offspring in adult life. However, the mechanisms via which this occurs remain elusive, precluding the
identification of potential therapy. Using an integrative approach at the isolated organ, cellular and molecular levels, we
tested the hypothesis that oxidative stress in the fetal heart and vasculature underlies the molecular basis via which prenatal
hypoxia programmes cardiovascular dysfunction in later life. In a longitudinal study, the effects of maternal treatment of
hypoxic (13% O2) pregnancy with an antioxidant on the cardiovascular system of the offspring at the end of gestation and
at adulthood were studied. On day 6 of pregnancy, rats (n=20 per group) were exposed to normoxia or hypoxia 6 vitamin
C. At gestational day 20, tissues were collected from 1 male fetus per litter per group (n=10). The remaining 10 litters per
group were allowed to deliver. At 4 months, tissues from 1 male adult offspring per litter per group were either perfusion
fixed, frozen, or dissected for isolated organ preparations. In the fetus, hypoxic pregnancy promoted aortic thickening with
enhanced nitrotyrosine staining and an increase in cardiac HSP70 expression. By adulthood, offspring of hypoxic pregnancy
had markedly impaired NO-dependent relaxation in femoral resistance arteries, and increased myocardial contractility with
sympathetic dominance. Maternal vitamin C prevented these effects in fetal and adult offspring of hypoxic pregnancy. The
data offer insight to mechanism and thereby possible targets for intervention against developmental origins of cardiac and
peripheral vascular dysfunction in offspring of risky pregnancy.
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Introduction
Cardiovascular disease is the greatest killer in the world today,
imposing a substantial burden on every nation’s health and wealth
[1]. The concept that environmental risk factors, such as smoking
and obesity, interact with our genetic makeup to determine
susceptibility to cardiovascular dysfunction is well accepted [2].
However, only comparatively recently, it has become apparent
that the quality of the prenatal environment may also play a role
[3,4]. In pregnancy complicated with adverse intrauterine
conditions, adaptations are enforced in the unborn child and
placenta, which can alter the development of key organs and
systems, such as the heart and circulation. Whilst they are
necessary to maintain viable pregnancy and sustain life before
birth, these adaptations come at a cost, triggering many biological
trade-offs for later life. Early insults at critical stages of
development may therefore lead to permanent changes in tissue
structure and function, a concept now known as programming [5].
The concept creates an exciting window of opportunity to halt the
development of cardiac and vascular dysfunction at its very origin,
bringing preventive medicine back into the womb. However, the
mechanisms underlying developmental programming remain
elusive, precluding the identification of potential avenues for
clinical therapy [6,7].
One of the most common adverse conditions in complicated
pregnancy is a reduction in oxygen delivery to the developing
young. The fetal defence to a short-term episode of hypoxia
includes the redistribution of blood flow away from peripheral
circulations towards essential vascular beds, such as those
perfusing the brain [8]. This brain-sparing effect is conserved
across all species studied from the reptilian and avian embryo to
the mammalian fetus, including the sheep, non-human and
human primate [9]. Should the duration of the hypoxic challenge
become prolonged, the initial homeostatic cardiovascular defences
persist [10,11]. In response to chronic hypoxia, sustained
redistribution of blood flow towards essential circulations ensures
fetal survival, but the adaptation claims a number of unwanted
side-effects. The best described is asymmetric fetal growth
restriction [11]. More recently, it has also been reported that
chronic hypoxia during pregnancy promotes an increase in fetal
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31017cardiac afterload, imposing a strain on the developing heart and
major vessels, leading to ventricular and aortic wall thickening
[12–14]. Severe hypoxia from early development may overpower
ventricular compensatory mechanisms, switching the cardiac
phenotype to one of myocardial thinning [15,16]. Other elegant
experiments have shown that prenatal hypoxia can alter cardiac
performance and increase its susceptibility to ischaemia-reperfu-
sion injury, in addition to promoting endothelial dysfunction in
adult life [16–26]. Thus, intrauterine hypoxia is not only an
immediate threat to fetal life, but is also provides a strong stimulus
for a developmental origin of heart and vascular disease. However,
the mechanisms through which prenatal hypoxia programmes
cardiac and endothelial dysfunction in adulthood have not been
identified. Therefore, no study to date has been able to prevent the
programming of cardiac and vascular dysfunction in adulthood by
prenatal hypoxia.
Hypoxia is a potent stimulus for the generation of reactive
oxygen species (ROS) [27]. Under physiological conditions, ROS
are important mediators of a wide variety of cell functions through
their actions on redox-sensitive transcription factors. However,
excessive generation of ROS and/or a fall in antioxidant defences
can lead to indiscriminate damage, resulting in cellular oxidative
stress [27]. Here, we tested the hypothesis that oxidative stress in
the fetal heart and vasculature underlies the molecular basis
through which prenatal hypoxia contributes to the developmental
programming of cardiac and endothelial dysfunction. The
hypothesis was tested using an integrative approach at the isolated
organ, cellular and molecular levels, in a longitudinal study in rats.
We investigated the effects of treatment of maternal hypoxic
pregnancies with an antioxidant on the cardiovascular system of
the offspring at two stages of life: in the fetal period at the end of
gestation and at 4 months of adult age.
Methods
Ethics Statement
Experiments were approved by the Ethical Review Committee
of the University of Cambridge and were carried out under the
UK Animals (Scientific Procedures) Act 1986.
Wistar rat pregnancies were established as described [13,28].
On day 6 of pregnancy, rats were randomly divided into 4 groups
(n=20 per group): control and hypoxic pregnancy, with and
without vitamin C treatment (5 mg.ml
21 maternal drinking water
freshly prepared every day). Pregnant rats subjected to hypoxia
were placed inside a chamber, which combined a PVC isolator
with a nitrogen generator [13,28]. Pregnancies undergoing
hypoxia were maintained at a constant inspired fraction of oxygen
of 13% from day 6 to 20 of gestation (term is ca. 21 days). At day
20 of gestation, one set of dams (n=10) from each group was
anesthetised with isoflurane and then maintained by a mixture of
ketamine (40 mgNkg
21) and xylazine (5 mgNkg
21) injected intra-
peritoneally. A maternal blood sample (1 ml in EDTA plus 0.5 ml
in metaphosphoric acid) for measurement of ascorbic acid was
taken by cardiac puncture, the pregnant uterus was exposed via a
mid-line incision and the anesthetised pups were killed via spinal
transection. Dams which had been housed in the hypoxic chamber
underwent the procedure while being spontaneously ventilated
with 13% O2 via a small cone. All fetuses and associated placentas
were isolated and weighed. Additional maternal and fetal blood
was taken for measurement of haematocrit in duplicate. In all
pups, the ano-genital distance was measured with digital callipers
for determination of sex. Only cardiovascular tissues associated
with one male pup per litter per measured outcome variable were
used to control for sex and within-litter variation. Therefore, the
fetal thorax (containing heart and aorta) was immersion fixed from
one male per litter per group (n=8) and the fetal heart was frozen
from a littermate male per litter per group (n=8) for subsequent
stereological, histological or molecular analyses. The remaining 10
litters per group were allowed to deliver. Following determination
of birth weight, litters were culled to 4 males and 4 females to
standardise nutritional access and maternal care [13]. At weaning,
only male offspring were raised to adulthood. At 4 months,
following weighing, 1 male from each litter per outcome variable
underwent euthanasia and tissues were either perfusion fixed for
stereological and histological analyses (n=8 per group), or frozen
for molecular analysis (n=8 per group), or dissected for the
isolated organ preparations (n=8 per group).
Determination of Ascorbic Acid
Reversed-phase high-performance liquid chromatography
(HPLC) with electrochemical detection was used to analyse ascorbic
acid, based on the method of Iriyama et al. with modifications
[29,30]. Maternal plasma previously acidified 1:1 with ice-cold 10%
metaphosphoric acid (MPA) was centrifuged and the supernatant
stored at 270uC. This supernatant was thawed on ice and 50 ml
added to 400 ml HPLC grade water, 50 ml of 50% MPA and 200 ml
of HPLC grade heptane. The samples were then mixed on a vortex
stirrer for 30 s prior to centrifugation at 13,000 r.p.m. for 5 min at
4uC. The lower (aqueous) layer was then removed and transferred
to a 0.8 ml HPLC vial. Aliquots of 20 ml were injected onto a
4.66250 mm, 5 mm C18 Apex II column with guard (Jones
Chromatography, Glamorgan, UK) and eluted with a 0.2 mol/l
K2HPO4-H3PO4 (pH 2.1) mobile phase containing 0.25 mmol/l
octane sulfonic acid at a flow rate of 1.0 ml/min. An electrochem-
ical detector (EG & G Instruments, Wokingham, UK) was used for
detection,with theworkingelectrode setat800 mVandasensitivity
0.2 mamp. Final concentrations for ascorbic acid were calculated
with external standards which were run simultaneously. The
coefficient of variation of analysis was ,5%, with a minimum
detection limit of 0.1 mM.
Stereology, histology and molecular biology
Fetal thoraces and adult hearts and aortas were embedded in
paraffin, exhaustively sectioned (10 mm, Leica RM 2235 micro-
tome, Germany) and processed for haematoxylin and eosin (H&E)
staining. Fetal aortas were also processed for immuno-reactivity to
nitrotyrosine (1:100, Cayman, California, USA). Nitrotyrosine is a
footprint for peroxinitrite generation and an established indicator
of vascular oxidative stress [27]. Sections were incubated in
primary antibody for 24 h at 4uC, after which they were incubated
in secondary antibody with bound gold particles (1:1000, Jackson
Research, Stratech Ltd., UK). Sections were developed using an
enhancer (Amersham, UK) and, then cover-slipped.
Quantitative analyses of fixed tissue were performed using an
Olympus BX-50 microscope, fitted with a motorised specimen
stage and microcator. All analyses were performed using the
Computer Assisted Stereology Toolbox (CAST) version 2.0
program (Olympus, Denmark), with the observer blind to the
treatment groups. Cardiac and aortic areas were determined using
a point grid, which was superimposed on the sections and viewed
using a 610 objective. Points falling on the left ventricular wall
plus inter-ventricular septum, left lumen, right ventricle wall and
right lumen, or aortic wall or lumen, were counted and the areas
were calculated as:
A obj ðÞ ~ap ðÞ |
X
P
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with each point and SP is the sum of points falling on the relevant
area, averaged over the sections.
Western blots were performed using 20 mg aliquots of protein
from fetal or adult hearts, resolved on 10% Tris-glycine-SDS
polyacrylamide gels (Bio-Rad, Hertfordshire, UK) and immobi-
lised on PVDF membranes. Antibodies to b-actin (1:50,000;
Sigma A5441, USA) or HSP70 (1:20,000; Stressgen Spa812C,
UK), a robust index of cardiac oxidative stress [21,27], were
incubated in 5% milk in 1% Tween-20 (TBS-T, Sigma-Aldrich,
UK) overnight at 4uC. Membranes were then incubated for
1 hour in a secondary antibody conjugated to horseradish
peroxidase (donkey anti-rabbit IgG or sheep anti-mouse IgG;
1:10,000, GE Healthcare, UK). Proteins were detected using
enhanced chemiluminescence (ECL, Amersham Biosciences, UK),
exposed to X-ray film and developed (Fuji FPM100A Processor).
Band densities were quantified and expressed relative to b-actin
(ImageJ software, NIH).
In vitro wire myography
Second order femoral arteries (internal diameter in mm:
N:269.9616.0; H: 299.5620.6; HC: 290.1620.7; NC:252.76
20.2, P=NS) were mounted on a four-chamber small-vessel wire
myograph (Multi Wire Myograph System 610 M, DMT, Den-
mark) [28,31]. Relaxant responses to sodium nitroprusside (SNP)
and to methacholine (SNP: 10
210–10
24; MetCh: 10
210–
10
26 mol.L
21) were determined after pre-contraction with
phenylephrine (PE, 10
25 mol.L
21). Additional concentration-
response curves to MetCh were determined following incubation
with either L-NAME (10
25 mol.L
21) alone or after both L-NAME
and indomethacin (10
26 mol.L
21). Between experiments, vessels
were washed repeatedly with Krebs solution and allowed to
equilibrate for at least 20 minutes. Concentration-response curves
were analysed using an agonist-response best-fit line. The maximal
relaxant response (%Rmax) was expressed as percentage of the
contraction induced by PE and the vascular sensitivity was
expressed as pD2 (-logEC50). The contribution of NO-dependent
mechanisms to the relaxation induced by MetCh was calculated
by subtracting the area under the curve (AUC) for MetCh – the
AUC for MetCh + LNAME. The contribution of NO-indepen-
dent mechanisms was calculated by the AUC for MetCh +
LNAME [31].
Langendorff preparation
The same adult male that provided femoral resistance vessels for
in vitro wire myography provided the heart for the isolated
Langendorff preparation, making investigation of cardiac and
vascular function in adulthood from the same individual animal
possible. Immediately after dissection, isolated hearts were
perfused at constant pressure (75 mmHg) under Langendorff
mode, with recirculating Krebs-Henseleit bicarbonate solution
containing (mM.L
21) 120 NaCl, 4.7 KCl, 1.2 MgSO2.7H2O, 1.2
KH2PO4, 25 NaHCO3, 10 glucose, and 1.3 CaCl2.2H2O, filtered
through a 5 mm cellulose nitrate filter (Millipore, Bedford, MA,
USA) and gassed with O2:CO2 (95:5) at 37uC. A small flexible
non-elastic balloon was inserted into the left ventricle through the
left atrium. The balloon was filled with saline and attached to a
rigid saline-filled catheter connected to a calibrated pressure
transducer (Argon Medical Devices, Texas, USA). The balloon
volume was adjusted to 150 ml to obtain left ventricular end
diastolic pressure (LVEDP) recording of approximately 5–
10 mmHg. After an initial 15-minutes stabilisation period, basal
heart rate (HR), left ventricular systolic pressure (LVSP) and
LVEDP were recorded. Left ventricular developed pressure
(LVDP) was calculated as LVSP-LVEDP. The rate-pressure
product (RPP) was calculated as HR6LVSP. The maximum first
derivative of the left ventricular pressure (dP/dtmax) was calculated
using an M-PAQ data acquisition system (Maastricht Programm-
ble AcQusition System, Netherlands). Cardiac responsiveness to
carbachol (carbamylcholine chloride, Sigma-Aldrich Co. Ltd,
Poole, UK) and to isoprenaline ((2)-isoproterenol (+)-bitartrate
salt, Sigma-Aldrich Co. Ltd, Poole, UK) was also investigated.
Data and statistical analyses
The experimental and statistical design was stringent to account
for sex differences and within litter variation. Comparisons of
variables derived from more than one offspring per litter, such as
birth weight, placental weight and placental efficiency were
performed using a Generalised Mixed Linear Model Analysis.
Other comparisons were of outcome variables derived from only
one male offspring per litter per experimental groups. These
comparisons were therefore assessed using a One Way ANOVA
with the Tukey post hoc test. For all comparisons, significance was
accepted when P,0.05.
Results
In fetal offspring at day 20 of gestation, the aortic wall thickness
was significantly enhanced in hypoxic pregnancy (Fig. 1A, 1B).
This occurred together with significant elevations in two indices of
oxidative stress in the fetal heart and vasculature: cardiac
expression of HSP70 and aortic wall nitrotyrosine staining,
respectively (Fig.1C, 1D). However, neither the cardiac weight
nor the morphology of the left or right ventricle was affected by
hypoxic pregnancy (Table 1). Maternal treatment with vitamin C
in hypoxic pregnancy restored the aortic wall thickness, aortic wall
nitrotyrosine staining and the cardiac expression of HSP70 to
values measured in normoxic pregnancy (Fig. 1A–D). In fetal
offspring, maternal treatment with vitamin C in normoxic
pregnancy did not affect the morphology of the heart or aorta,
or the levels of nitrotyrosine in the aortic wall or of HSP70 in the
heart (Table 1; Fig. 1A–D).
In adult offspring at 4 months of age, the endothelium-
independent and endothelium-dependent relaxation in femoral
resistance arteries was evaluated by generating cumulative
concentration-response curves to the NO-donor sodium nitro-
prusside and to the acetylcholine mimetic methacholine, respec-
tively. To determine the partial contributions of NO-dependent
and NO-independent mechanisms to the endothelial dysfunction,
additional concentration-response curves were determined follow-
ing incubation with the NO synthase blocker L-NAME alone or
after both L-NAME and the prostaglandin synthase inhibitor
indomethacin. Femoral resistance arteries of adult offspring from
hypoxic pregnancies showed diminished dilatation to nitroprusside
and markedly impaired relaxation to methacholine via NO-
dependent mechanisms (Fig. 2A–C). Maternal treatment with
vitamin C restored the relaxant response to methacholine, but not
to sodium nitroprusside, in femoral resistance arteries of adult
offspring from hypoxic pregnancies via increasing the contribution
of NO-independent mechanisms (Fig. 2A–C). Intriguingly,
femoral resistance arteries of adult offspring from normoxic
pregnancies treated with vitamin C also showed markedly
impaired relaxation to methacholine via NO-dependent mecha-
nisms (Fig. 2A–C).
In adult offspring at 4 months of age, the body and cardiac
weights were similar across all four groups studied. Neither the
morphology of the heart or aorta or the expression levels of
cardiac HSP70 were affected by hypoxic pregnancy or treatment
Prenatal Hypoxia and Programming
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from adult offspring of hypoxic pregnancy showed significantly
enhanced values for dP/dtmax and for the rate-pressure product
(Fig. 3A and 3B). While the chronotropic response to the muscarinic
agonist carbachol was significantly suppressed, this was markedly
enhanced to the b1-adrenoreceptor agonist isoprenaline (Fig. 3C
and 3D). Maternal treatment with vitamin C in hypoxic pregnancy
restored these cardiac responses towards values measured in adult
offspring from normoxic pregnancy. Vitamin C in normoxic
pregnancy did not have any effect on cardiac responses in adult
offspring (Fig. 3A–D). Basal heart rate, left ventricular developed
pressure and left ventricular end-diastolic pressure in hearts of adult
offspring were unaffected by hypoxic pregnancy or pregnancy
treated with vitamin C (Table 1).
Maternal plasma levels of ascorbic acid were increased by
similar extents at day 20 of gestation in normoxic and hypoxic
pregnancy following maternal vitamin C (Table 1). Maternal and
fetal haematocrit increased by similar extents in hypoxic
pregnancy whether untreated or treated with vitamin C
(Table 1). In normoxic pregnancy, maternal food intake did not
vary significantly during gestation and averaged 29.460.7 g per
day. Neither hypoxic pregnancy nor maternal treatment with
vitamin C affected daily maternal food intake (H: 26.660.5 g;
HC: 27.661.0 g; NC: 28.160.7 g.d
21) or litter size (Table 1).
However, birth weight was significantly enhanced in both
normoxic and hypoxic pregnancy following maternal treatment
with vitamin C (Table 1). Hypoxic pregnancy with or without
vitamin C increased placental weight (Table 1). Placental
efficiency, calculated as the ratio of fetal body weight to placental
weight at day 20 of gestation, revealed that hypoxic pregnancies
had slightly lower calculated values for placental efficiency relative
to controls (H=5.5960.11, n=49 vs. C=5.6560.16, n=38;
P,0.05). Maternal treatment with vitamin C did not affect
placental efficiency in normoxic or hypoxic pregnancy
(NC=5.8760.09, n=60; HC=5.1760.09, n=60).
Discussion
The data show that chronic prenatal hypoxia, leading to a
significant increase in fetal haematocrit, promotes fetal aortic
Figure 1. Fetal aorta and heart. Photomicrographs of individual examples of sections of the fetal aorta are shown in a. Bar scale is 100 mm. Values
are mean6S.E.M. of the wall to lumen area ratio b; the density of nitrotyrosine staining in the aortic wall c, and the protein expression of HSP70 in the
fetal heart d. Groups are: Normoxia, n=8 (N,%), Hypoxia, n=8 (H,&), Hypoxia+Vitamin C, n=8 (HC, red histogram) and Normoxic+Vitamin C, n=8
(NC, blue histogram). Significant (P,0.05) differences are: * vs. all, { vs. H, One-Way ANOVA with Tukey Test.
doi:10.1371/journal.pone.0031017.g001
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vasculature by the end of gestation. By adulthood, these effects
resolve but prenatal chronic hypoxia sets a functional deficit in
both the heart and the peripheral circulation. Adult offspring
from chronically hypoxic pregnancies show enhanced myocardial
contractility due to sympathetic dominance and NO-dependent
endothelial dysfunction in peripheral resistance vessels. The
effects of chronic prenatal hypoxia on the fetal and adult
offspring cardiovascular system are prevented by maternal
treatment with vitamin C during pregnancy. While it is
established that chronic prenatal hypoxia programmes cardio-
vascular disease, the mechanisms mediating this programming
Table 1. Maternal and offspring data.
N H HC NC
Mother ascorbic acid 18.762.1 20.062.5 31.263.0 32.262.4*
(mmol.L
21) (n=7) (n=7) (n=7) (n=7)
haematocrit 30.260.5 35.860.2* 36.160.4* 30.960.7
(%) (n=7) (n=7) (n=7) (n=7)
Offspring at the end of gestation haematocrit 34.160.2 41.160.5* 41.960.4* 35.360.7
(%) (n=7) (n=7) (n=7) (n=7)
birth weight 6.360.6 6.260.5 6.660.5* 6.860.5*
(g) (n=42) (n=43) (n=35) (n=33)
placental weight 0.6160.01 0.6660.02* 0.6960.01* 0.5860.01
(g) (n=63) (n=49) (n=60) (n=60)
litter size 13.360.9 14.060.5 12.260.9 12.760.6
(n) (n=7 dams) (n=6 dams) (n=6 dams) (n=7 dams)
absolute heart weight 25.461.7 26.061.0 24.461.1 22.660.5
(mg) (n=18) (n=16) (n=16) (n=18)
relative heart weight 0.7060.02 0.7160.02 0.6760.03 0.6760.01
(%) (n=18) (n=16) (n=16) (n=18)
Left ventricular area 1.5560.05 1.4960.06 1.6760.07 1.6460.05
(mm
2) (n=6) (n=6) (n=8) (n=7)
Right ventricular area 0.9960.06 0.8860.08 1.0360.07 1.0160.08
(mm
2) (n=6) (n=6) (n=8) (n=7)
Offspring at 4 months body weight 550.969.0 540.9612.6 554.468.3 527.6611.5
(g) (n=25) (n=20) (n=23) (n=23)
absolute heart weight 1.760.1 1.660.1 1.660.1 1.660.1
(g) (n=25) (n=20) (n=23) (n=23)
relative heart weight 0.3060.01 0.3060.01 0.2960.01 0.3160.01
(%) (n=25) (n=20) (n=23) (n=23)
Left ventricular area 27.163.2 32.761.7 32.763.9 28.264.4
(mm
2) (n=5) (n=5) (n=6) (n=6)
Right ventricular area 13.561.3 15.862.4 13.561.3 11.261.6
(mm
2) (n=5) (n=5) (n=6) (n=6)
Cardiac HSP70 protein 0.8060.09 0.8160.09 0.7860.08 0.7960.05
expression (/b actin) (n=8) (n=8) (n=8) (n=8)
Aorta wall:lumen area 0.2360.02 0.2260.01 0.2360.01 0.2260.01
ratio (n=8) (n=8) (n=8) (n=8)
heart rate 243620 255621 235614 260614
(bpm) (n=6) (n=6) (n=7) (n=7)
LVDP 84.867.9 104.769.7 100.065.2 92.464.8
(mmHg) (n=6) (n=6) (n=7) (n=7)
LVEDP 7.161.8 9.861.3 8.161.6 11.262.5
(mmHg) (n=6) (n=6) (n=7) (n=7)
Values are mean6S.E.M. for dams and offspring of Normoxic (N), Hypoxic (H), Hypoxic+Vitamin C (HC) and Normoxic+Vitamin C (NC) pregnancy. Placental weight, fetal
haematocrit and fetal heart weight were taken at gestational day 20. Values for heart rate, left ventricular developed pressure (LVDP) and left ventricular end diastolic
pressure (LVEDP) were taken from the isolated heart preparations. Significant (P,0.05) differences are:
*vs. normoxia, Mixed Linear Model for birth weight, placental weight, fetal absolute and relative heart weights; ANOVA+Tukey Test for all other variables.
doi:10.1371/journal.pone.0031017.t001
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potential therapeutic targets for clinical intervention. Therefore,
the primary novelty of the discoveries reported here is that
programming by prenatal chronic hypoxia of cardiac and
vascular dysfunction in adulthood follows the induction of
oxidative stress in the fetal heart and vasculature, and that
cardiac and endothelial dysfunction in adulthood can both be
prevented by maternal treatment with antioxidants during
pregnancy. Therefore, the study supports the hypothesis tested,
and the new discoveries provide insight to mechanism and
intervention using a broad range of measurements at several
levels in a single longitudinal experiment.
Figure 2. Femoral artery vasodilator function in adulthood. Values are mean6S.E.M. for the concentration-response curve (maximal
response, %Rmax, and sensitivity, pD2) to sodium nitroprusside (SNP) a and to methacholine (MetCh) b, and for the nitric oxide (NO) dependent and
independent components (area under the curve, AUC) of the endothelial dependent vasorelaxation c in femoral resistance arteries isolated from 4
month adult offspring. Concentration-response curves were analysed using an agonist-response best-fit line. The maximal relaxant response (%Rmax)
was expressed as percentage of the contraction induced by PE and the vascular sensitivity was expressed as pD2 (-logEC50). The contribution of NO-
dependent mechanisms to the relaxation induced by MetCh was calculated by subtracting the area under the curve (AUC) for MetCh – the AUC for
MetCh + LNAME. The contribution of NO-independent mechanisms was calculated by the AUC for MetCh + LNAME [31]. Groups are: Normoxia, n=8
(N, white symbols), Hypoxia, n=8 (H, black symbols), Hypoxia+Vitamin C, n=6 (HC, red symbols) and Normoxic+Vitamin C, n=8 (NC, blue symbols).
Significant (P,0.05) differences are: * vs. N, { vs. H, One-Way ANOVA with Tukey Test.
doi:10.1371/journal.pone.0031017.g002
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Several studies have reported that chronic hypoxia during
development promotes a vasoconstrictor phenotype in peripheral
resistance circulations of fetal offspring. Chronic hypoxia may
achieve this by increasing sympathetic innervation [12,32] and the
responsiveness of peripheral circulations to a1-adrenergic agonists
[33] in the fetus. In addition, chronic hypoxia may reduce fetal
vasodilator capacity by affecting endothelial function. For
instance, the interaction between O2
N2: NO promotes a vascular
oxidant ratio that is also an important determinant of vascular
tone [34], and we have shown that hypoxia can manipulate this
vascular oxidant ratio in fetal resistance circulations towards
vasoconstriction [35]. Two studies have further reported that this
vasoconstrictor phenotype triggered by developmental hypoxia is
not only present in fetal life, but that chronic prenatal hypoxia can
programme permanent endothelial dysfunction in resistance
circulations of the adult offspring [25,26]. Here, we show that
maternal treatment with antioxidants during pregnancy can
restore this programmed impaired vasodilator phenotype in adult
offspring, providing new evidence for the mechanism mediating
the developmental programming of endothelial dysfunction by
prenatal chronic hypoxia to be due to vascular oxidative stress.
It is interesting that the balance of redox modulation of vascular
tone, imposed by the O2
N2: NO ratio, may be tipped in either
direction to promote disequilibrium, as maternal treatment with
vitamin C in normoxic pregnancy also promoted endothelial
dysfunction. Maternal antioxidant supplementation may therefore
only restore the offspring vascular dysfunction in pregnancy
conditions associated with increased O2
N2 generation and vascular
oxidative stress. Conversely, antioxidant treatment in healthy
conditions where the offspring vascular physiology is already
replenished with an appropriate redox balance may, in fact, lead
to excess NO bioavailability, tipping the balance in the opposite
direction. Excess NO bioavailability is known to promote
peroxynitrite generation, thereby triggering mechanistic side-
effects resembling those of vascular oxidative stress [27]. The
implications of these data are that maternal treatment with
antioxidants may provide possible therapy against the program-
ming effects on vascular dysfunction in pregnancy complicated by
fetal hypoxia, such as during placental insufficiency, preeclampsia,
gestational diabetes or high altitude pregnancy. However, the data
underline that excessive antioxidant supplementation in healthy
pregnancy may, in effect, be detrimental and is not to be
recommended.
Figure 3. Cardiac function in adulthood. Values are mean6S.E.M. for the dP/dt max a, the heart rate-pressure product (RPP) b; and the heart rate
responses to 10–6 M Carbachol c and to 10–7 M Isoprenaline d. Groups are: Normoxia, n=6 (N,%), Hypoxia, n=6 (H, &), Hypoxia+Vitamin C, n=7
(HC, red histogram) and Normoxic+Vitamin C, n=7 (NC, blue histogram). Significant (P,0.05) differences are: * vs. all, One-Way ANOVA with Tukey
Test.
doi:10.1371/journal.pone.0031017.g003
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hypoxia promotes thickening of the aortic wall in the fetal
offspring [12–15]. At least five independent clinical studies have
reported that babies from pregnancies complicated by placental
insufficiency show aortic wall thickening [36–40]. This is
particularly relevant in the clinical setting, as thickening of the
aortic wall has been hailed as a key component in the aetiology of
coronary heart disease [41] and it is also as the first physical sign in
the development of atherosclerosis [41]. Further, measurement of
aortic pulse-wave velocity rather than of systolic blood pressure is
recognised to be a better indicator of later cardiovascular disease,
including impaired coronary artery flow and left ventricular
dysfunction [42]. The peripheral vasoconstrictor phenotype and
aortic wall thickening in offspring of hypoxic pregnancies in the
present study may therefore be linked, as there is general
agreement that vascular remodelling of this type can result from
an increase in cardiac afterload [15,43]. Accordingly, maternal
treatment with antioxidants in hypoxic pregnancy restored aortic
wall thickening and the endothelial dysfunction in resistance
circulations in the offspring.
Effects on the heart
A number of comprehensive studies have also shown that
developmental hypoxia can programme cardiac dysfunction in
adult offspring. Adverse programmed effects include altered
myocardial structure and metabolism, a decline in cardiac
performance and heightened cardiac susceptibility to adult
ischaemic injury [15–24]. These experimental studies are of
substantial clinical relevance, as it has now also been reported that
children from complicated pregnancies show changes in cardiac
morphology and function [40]. Here, we show that chronic
prenatal hypoxia has permanently altered the mechanical
properties of the myocardium and its inherent response to
chemical mediators of contractile force. An increase in dP/dtmax
is an established index of increased myocardial contractility and an
increase in the rate-pressure product is associated with increased
myocardial work load and oxygen consumption [44]. The
mechanism driving the enhanced myocardial contractility is
enhanced responsiveness to b1-adrenoreceptor stimulation, cou-
pled with decreased reactivity to muscarinic agonists. It is possible
that the increase in myocardial contractility occurs in response to
the increased afterload derived from the increased peripheral
vascular impedance. We also show that the effects of chronic
prenatal hypoxia on the heart of adult offspring can be prevented
by maternal antioxidant treatment during pregnancy, providing
new evidence for the mechanism driving the developmental
programming of heart dysfunction by prenatal hypoxia to also be
secondary to oxidative stress. Maternal treatment with antioxi-
dants may prevent programmed autonomic influences on the adult
heart triggered by prenatal hypoxia by altering the bioavailability
of NO, as the gaseous neurotransmitter can enhance myocardial
vagal dominance [45]. Sustained increases in myocardial contrac-
tility due to heightened sympathetic excitation and diminished
parasympathetic reactivity are strongly associated with cardiovas-
cular disease, and this cardiac phenotype is a known predictor of
eventual heart failure in humans [45,46].
Dose of vitamin C
In vascular endothelial cells, nitric oxide (NO) is produced
constitutively in vivo, but it is rapidly inactivated by superoxide
anion (
NO2
2) to produce
NONOO
2 [47]. Although the availability
of
NO2
2 in tissues is strictly limited by the abundance of superoxide
dismutase (SOD), which is able to dismutate
NO2
2 at a rapid rate
constant [48], NO can still compete effectively with SOD for
NO2
2. Jackson and colleagues [49] reported that vitamin C could
scavenge
NO2
2 at low concentrations, but it could only prevent the
impairment by
NO2
2 of endothelium derived NO-mediated
arterial relaxation at much higher physiological concentrations.
Therefore, the capacity of vitamin C to scavenge
NO2
2 and its
ability to prevent the interaction between NO and
NO2
2 appear to
occur at very different concentrations in vivo. The dose of vitamin
C used in the present study was derived from a previous study in
our laboratory which achieved elevations in circulating ascorbate
concentrations, enabling it to act as an antioxidant in vivo in ovine
pregnancy [35], thereby justifying the antioxidant dosing regimen.
In rat pregnancy, this equated to ca. 0.9 g kg
21?d
21 of vitamin C
administration. Although this dose of vitamin C far exceeds that
given to pregnant women, for instance in all reported clinical trials
against preeclampsia (1 g per day per woman [50–54]), the
increment from baseline in circulating ascorbate concentrations
measured in dams in the present study was of ca. 70% and,
therefore, similar to the increment achieved in pregnant women in
the VIP trial following maternal vitamin C administration [50].
Since treatment of human patients with high doses of vitamin C
can promote oxaluria and the risk of kidney stones [55], vitamin C
may not be the antioxidant of choice for human therapy in
complicated pregnancy. However, the study provides the proof of
principle that maternal antioxidant treatment does protect against
the programming of cardiovascular dysfunction in offspring of
pregnancy complicated by fetal hypoxia.
Maternal food intake and biometry
Previous studies have shown that prenatal hypoxia in the last
third of gestation decreases maternal food intake and induces
disproportionate fetal growth restriction [11,13,25]. In our study,
developmental hypoxia throughout most of gestation did not affect
maternal food intake or fetal growth, but it increased placental
weight. These differences are important because they highlight
that programming of cardiovascular dysfunction is due to prenatal
hypoxia alone independent of maternal nutrition. Further, the
model shows that alterations in fetal and/or postnatal growth are
not a prerequisite for developmental programming. The differ-
ences in the placental and fetal phenotypes between the studies are
likely due to the differential temporal growth demands of the
placenta and fetus during pregnancy. In the rat, whereas placental
growth starts early in gestation and continues throughout
pregnancy, fetal growth is exponential and maximal by the end
of gestation [56]. Therefore, early-onset hypoxia may stimulate
greater than normal placental growth, cushioning the adverse
effects of the challenge on fetal growth. Accordingly, studies of
human pregnancy at high altitude have reported improved
placental vascularisation with increased placental capillary diam-
eter, capillary length and capillary volume [57,58]. Further data
reported in this study show that maternal treatment with vitamin
C increased birth weight in both normoxic and hypoxia
pregnancy. The mechanism mediating this may be secondary to
the increased NO bioavailbility enhancing placental perfusion, as
we have previously also reported that maternal treatment with
antioxidants can enhance umbilical blood flow and fetal growth
via NO-dependent mechanisms [59,60].
Clinical perspective
A meta-analysis of randomised clinical trials on the effectiveness
of antioxidants in cardiovascular risk reduction has shown
invariably negative results [61]. Without exception, all of these
studies have been on patients with established cardiovascular
disease, providing evidence that antioxidant treatment is unlikely
to rectify cardiovascular function once disease is established. Our
Prenatal Hypoxia and Programming
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31017studies provide a different approach, addressing the effects of
antioxidant therapy in the fetus as a preventive strategy, halting
the slow development of cardiovascular dysfunction across the life
span at its very origin. Therefore, the data offer insight into
mechanism and possible targets for clinical intervention against
the developmental programming of heart and peripheral vascular
dysfunction in risky pregnancy.
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